Clinical Trial Update: QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating QL1706 in combination with chemotherapy for advanced immune-mediated non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING